QLT/CIBA Vision Visudyne
Executive Summary
NDA filing for verteporfin expected in mid-1999, following initial 12-month analysis of pivotal Phase III data, the companies announce Jan. 5. Early results from the 609-patient Treatment of AMD with Photodynamic therapy trial show that Visudyne stabilized or improved vision in 61.4% of patients with "wet" age-related macular degeneration compared to 45.9% of patients treated with placebo. Less than 2% of patients in the Visudyne arm withdrew from the study due to adverse events, data show
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth